The novel potent GSK3 inhibitor AF3581 reverts fragile X syndrome phenotype

• Published in: Human molecular genetics Vol. 31; no. 6; pp. 839 - 849
• Main Authors: Porceddu, Pier Francesca, Ciampoli, Mariasole, Romeo, Elisa, Garrone, Beatrice, Durando, Lucia, Milanese, Claudio, Di Giorgio, Francesco Paolo, Reggiani, Angelo
• Format: Journal Article
• Language: English
• Published: England 21.03.2022
• Subjects: Animals; Disease Models, Animal; Fragile X Mental Retardation Protein - genetics; Fragile X Mental Retardation Protein - metabolism; Fragile X Syndrome - drug therapy; Fragile X Syndrome - genetics; Glycogen Synthase Kinase 3 - genetics; Glycogen Synthase Kinase 3 - metabolism; Mice; Mice, Knockout; Phenotype
• ISSN: 0964-6906; 1460-2083
• DOI: 10.1093/hmg/ddab251

Glycogen-synthase kinase 3 (GSK3) is a kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules. The enzyme is involved in the regulation of many cellular processes and aberrant activity of GSK3 has been linked to several disease conditions such as fragile X syndrome (FXS). Recent evidences demonstrating an increased activity of GSK3 in murine models of FXS, suggest that dysregulation/hyperactivation of the GSK3 path should contribute to FXS development. A likely possibility could be that in FXS there is a functional impairment of the upstream inhibitory input over GSK3 thus making overactive the kinase. Since GSK3 signaling is a central regulatory node for critical neurodevelopmental pathways, understanding the contribution of GSK3 dysregulation to FXS, may provide novel targets for therapeutic interventions for this disease. In this study we used AF3581, a potent GSK3 inhibitor that we recently discovered, in an in vivo FXS mouse model to elucidate the crucial role of GSK3 in specific behavioral patterns (locomotor activity, sensorimotor gating and social behavior) associated with this disease. All the behavioral alterations manifested by Fmr1 knockout mice were reverted after a chronic treatment with our GSK3 inhibitor, confirming the importance of this pathway as a therapeutic target.